Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions.

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to 'Strong Buy'.

Cobenfy, which has a potential peak sales estimate of over $7 billion. Since 2022, Bristol Myers Squibb has reduced its outstanding shares from 2.15 billion to 2.03 billion through $13 billion in ...

Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...

notably the FDA approval of Cobenfy and the promising regulatory path of Opdivo-related treatments. These achievements underscore Bristol Myers Squibb's commitment to advancing its pipeline in ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against stocks that Jim Cramer discusses with insights on President Trump’s Sovereign Wealth ...

We recently published a list of Jim Cramer’s Latest Portfolio: Top 10 Stocks to Watch. In this article, we are going to take ...

The analyst’s rating is backed by a strong launch performance of Bristol-Myers Squibb Company (NYSE:BMY)’s COBENFY, which continues to demonstrate strong sales momentum since its introduction ...